Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Microba Life Sciences Limited ( (AU:MAP) ) just unveiled an announcement.
Microba Life Sciences Limited announced the cessation of Dr. Hyungtae Kim as a director, effective November 19, 2025. Dr. Kim, who was a director nominee of Macrogen, Inc., held 17,828,431 ordinary fully paid shares in the company. This change in directorship may influence the company’s strategic direction and stakeholder relationships, particularly with Macrogen, Inc.
The most recent analyst rating on (AU:MAP) stock is a Buy with a A$0.14 price target. To see the full list of analyst forecasts on Microba Life Sciences Limited stock, see the AU:MAP Stock Forecast page.
More about Microba Life Sciences Limited
Microba Life Sciences Limited operates in the biotechnology industry, focusing on microbiome analysis and related services. The company specializes in providing insights into gut health and personalized health solutions through advanced microbiome testing.
Average Trading Volume: 677,689
Technical Sentiment Signal: Sell
Current Market Cap: A$44.45M
Learn more about MAP stock on TipRanks’ Stock Analysis page.